← Leaderboards
Mark Robert Nicolls
University Of Colorado Denver
$22,256,364
Attributed
$30,729,405
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,729,405 · 16
VA$0 · 2
By mechanism
R01$19,684,695 · 7
T32$3,211,945 · 1
P01$2,981,932 · 2
U01$1,708,641 · 1
K12$1,337,709 · 1
R21$770,000 · 1
Top collaborators
- Marlene Rabinovitch15 shared
- David N Cornfield10 shared
- Michael P Snyder9 shared
- Gundeep Singh Dhillon4 shared
- Bali Pulendran4 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Scott D Sagel$756,212
- Livia Agnes Veress$8,631,906
- Richard W Vandivier$1,718,665
- Theresa A Laguna$1,514,917
- Kelly D. Sullivan$6,280,565
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungBlood VesselsInjuryInflammationCellsEndothelial CellsGrantMediatingSignal TransductionInflammatoryPreventChronicPathway InteractionsPulmonary HypertensionT-LymphocyteTissuesFutureBiologyTransplantationPhenotypePulmonary Arterial HypertensionGeneticLifeDesign
Grant awards (82)
BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension$645,730
R01 · FY2025 · HL
Vaccination responses in lung transplant recipients$418,535
U01 · FY2025 · HL · contact PI
Stanford Training Program in Lung Biology$148,891
T32 · FY2025 · HL · contact PI
BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension$680,174
R01 · FY2024 · HL
Regulatory T Cells and Pulmonary Hypertension$570,589
R01 · FY2024 · HL · contact PI
Vaccination responses in lung transplant recipients$412,076
U01 · FY2024 · HL · contact PI
Stanford Training Program in Lung Biology$408,155
T32 · FY2024 · HL · contact PI
BMPR2 mutations, Neointimal Transformation and Pulmonary Arterial Hypertension$0
I01 · FY2024 · VA · contact PI
Regulatory T Cells and Pulmonary Hypertension$602,055
R01 · FY2023 · HL · contact PI
Vaccination responses in lung transplant recipients$422,438
U01 · FY2023 · HL · contact PI
Stanford Training Program in Lung Biology$391,989
T32 · FY2023 · HL · contact PI
BMPR2 mutations, Neointimal Transformation and Pulmonary Arterial Hypertension$0
I01 · FY2023 · VA · contact PI
Regulatory T Cells and Pulmonary Hypertension$627,446
R01 · FY2022 · HL · contact PI
A Critical Role for Leukotriene B4 in Lymphedema$497,241
R01 · FY2022 · HL · contact PI
Vaccination responses in lung transplant recipients$455,592
U01 · FY2022 · HL · contact PI
Critical Role for Microvasculature in Airway Transplantation$408,029
R01 · FY2022 · HL · contact PI
Stanford Training Program in Lung Biology$382,407
T32 · FY2022 · HL · contact PI
BMPR2 mutations, Neointimal Transformation and Pulmonary Arterial Hypertension$0
I01 · FY2022 · VA · contact PI
Regulatory T Cells and Pulmonary Hypertension$655,254
R01 · FY2021 · HL · contact PI
A Critical Role for Leukotriene B4 in Lymphedema$559,566
R01 · FY2021 · HL · contact PI
Critical Role for Microvasculature in Airway Transplantation$445,841
R01 · FY2021 · HL · contact PI
Stanford Training Program in Lung Biology$366,428
T32 · FY2021 · HL · contact PI
BMPR2 mutations, Neointimal Transformation and Pulmonary Arterial Hypertension$0
I01 · FY2021 · VA · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$705,629
R01 · FY2020 · HL
A Critical Role for Leukotriene B4 in Lymphedema$560,491
R01 · FY2020 · HL · contact PI
Critical Role for Microvasculature in Airway Transplantation$483,194
R01 · FY2020 · HL · contact PI
Stanford Training Program in Lung Biology$190,662
T32 · FY2020 · HL · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$721,683
R01 · FY2019 · HL
A Critical Role for Leukotriene B4 in Lymphedema$672,492
R01 · FY2019 · HL · contact PI
Critical Role for Microvasculature in Airway Transplantation$511,006
R01 · FY2019 · HL · contact PI
Stanford Training Program in Lung Biology$345,001
T32 · FY2019 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$757,680
R01 · FY2018 · HL
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$732,720
R01 · FY2018 · HL
Critical Role for Microvasculature in Airway Transplantation$349,325
R01 · FY2018 · HL · contact PI
Stanford Training Program in Lung Biology$333,890
T32 · FY2018 · HL · contact PI
Role of Macrophage-Derived Leukotriene B4 (LTB4) in Pulmonary Hypertension$314,613
P01 · FY2018 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$1,210,211
R01 · FY2017 · HL
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$776,362
R01 · FY2017 · HL
Critical Role for Microvasculature in Airway Transplantation$349,265
R01 · FY2017 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$338,160
K12 · FY2017 · HL
Stanford Training Program in Lung Biology$324,594
T32 · FY2017 · HL · contact PI
Role of Macrophage-Derived Leukotriene B4 (LTB4) in Pulmonary Hypertension$314,613
P01 · FY2017 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$1,246,582
R01 · FY2016 · HL
Critical Role for Microvasculature in Airway Transplantation$351,795
R01 · FY2016 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$344,651
K12 · FY2016 · HL
Stanford Training Program in Lung Biology$319,928
T32 · FY2016 · HL · contact PI
Role of Macrophage-Derived Leukotriene B4 (LTB4) in Pulmonary Hypertension$314,613
P01 · FY2016 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$843,057
R01 · FY2015 · HL
Elafin to prevent acute rejection following lung transplantation$473,638
P01 · FY2015 · HL · contact PI
Critical Role for Microvasculature in Airway Transplantation$356,345
R01 · FY2015 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$262,820
K12 · FY2015 · HL
Role of Macrophage-Derived Leukotriene B4 (LTB4) in Pulmonary Hypertension$245,776
P01 · FY2015 · HL · contact PI
Leukotriene B4-mediated Pulmonary Arterial Hypertension$173,871
R01 · FY2015 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension$387,297
R56 · FY2014 · HL · contact PI
Elafin to prevent acute rejection following lung transplantation$320,813
P01 · FY2014 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$267,878
K12 · FY2014 · HL
A Critical Role for the Microvasculature in Airway Transplantation$339,332
R01 · FY2013 · HL · contact PI
Elafin to prevent acute rejection following lung transplantation$311,646
P01 · FY2013 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$124,200
K12 · FY2013 · HL
The Role of Complement in Airway Microvascular Disease$0
I01 · FY2013 · VA · contact PI
A Critical Role for the Microvasculature in Airway Transplantation$356,382
R01 · FY2012 · HL · contact PI
Elafin to prevent acute rejection following lung transplantation$327,360
P01 · FY2012 · HL · contact PI
The Role of Complement in Airway Microvascular Disease$0
I01 · FY2012 · VA · contact PI
A Critical Role for the Microvasculature in Airway Transplantation$363,037
R01 · FY2011 · HL · contact PI
Elafin to prevent acute rejection following lung transplantation$358,860
P01 · FY2011 · HL · contact PI
The Role of Complement in Airway Microvascular Disease$0
I01 · FY2011 · VA · contact PI
The Role of Complement in Airway Microvascular Disease$0
I01 · FY2011 · VA · contact PI
A Critical Role for the Microvasculature in Airway Transplantation$367,556
R01 · FY2010 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$360,581
R01 · FY2009 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$240,149
R01 · FY2009 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$58,013
R01 · FY2009 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$360,581
R01 · FY2008 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$360,581
R01 · FY2007 · HL · contact PI
An Autoimmune Basis for Pulmonary Hypertension.$384,850
R01 · FY2006 · HL · contact PI
Viability Assay for Human Islet Transplantation$385,000
R21 · FY2005 · DK
Viability Assay for Human Islet Transplantation$385,000
R21 · FY2004 · DK
MECHANISMS OF ALLOGRAFT TOLERANCE$128,980
K08 · FY2003 · DK
Mechanisms of Allograft Tolerance$71,812
R03 · FY2003 · DK
Mechanisms of Allograft Tolerance$71,094
R03 · FY2003 · DK
MECHANISMS OF ALLOGRAFT TOLERANCE$127,980
K08 · FY2002 · DK
MECHANISMS OF ALLOGRAFT TOLERANCE$123,660
K08 · FY2001 · DK
MECHANISMS OF ALLOGRAFT TOLERANCE$123,660
K08 · FY2000 · DK